As the leading investment platform in the industry, Guangfa Ganhe and Guangfa Shunde have been actively deployed in the medical technology industry. By April 30, 2020, Guangfa Ganhe had invested in four projects 14 in the pharmaceutical field, with an investment of more than 350 million yuan, of which Borui Pharmaceutical (29.330, -0.0 1, -0.03%) (rights protection) engaged in the research and development and production of pharmaceutical intermediates, raw materials and preparations with high technical barriers was in 2063. By the end of 20 19 and 12, CGB Shunde Medical and Health Investment Department managed 6 RMB funds and 1 USD funds, with 55 investment projects, of which 12 projects had been IPO, and 2 projects were acquired and withdrawn by listed companies.

This roadshow of post-investment projects in the medical industry shows the long-term investment achievements of Guangfa Ganhe and Guangfa Xinde in the medical industry and their strong support for the stable and healthy development of medical technology enterprises in a special period. Cloud roadshow not only broke the previous time and space restrictions, but also added impetus to the financing and rapid development of outstanding startups. In the future, Guangfa Ganhe and Guangfa Shunde will continue to support the national innovation-driven development strategy, pay attention to and increase investment in the medical field, and help China medical enterprises to actively explore in the field of innovation.